Company Events  

• October 9th, 2008: Vitalea Science's Open House - a unique opportunity to view the most exciting technological advance in drug development over recent decades: the BioMICADAS™, a product of the Paul Scherrer Institut (Switzerland), and Vitalea Science. Click here for invitation.
• Dr. John Vogel will discuss "Accelerator Mass Spectrometry and Microdosing" during the CACO-CA luncheon seminar at the Crown Plaza Hotel in Foster City, CA in March 21, 2008 from 11:00am to 1:pm.  To register, click here
• May, 2007: Vitalea Science, Inc. completed a GLP inspection from independent, external auditors, and with the addition of a veteran Quality Assurance Director, became a fully GLP compliant analytical facility. 
• January, 2007: Dr. Hans-Arno Synal and Vitalea Science, Inc. presented the design and performance of the compact particle accelerator Bio-MICADAS at the annual Lab Automation at the Palm Springs Convention Center, Palm Springs, CA, January 27-31,2007.  
• July, 2006: Vitalea Science and PSI-ETH (Zurich) entered into a collaborative arrangement to develop and market the compact particle accelerator (MICADAS) for biomedical applications.
• July, 2005: Vitalea Science and Radiant Research, Inc. completed the proof-of-concept microdose study of Zidovudine in a healthy volunteer.  
• January, 2005: Vitalea completes build-out of new Laboratory Space. Moves toward Good Laboratory Practice Certification.
• July, 2004:  Vitalea Science completes a landmark human microdose study of an anti-HIV drug compound.
• June, 2004: Vitalea Science provides AMS-research services in support of a microdosing study for a major industrial partner .
• March, 2004:   Vitalea Science signs a Memorandum of Agreement with The University of California at Davis   to develop diagnostic tools for estrogen metabolism in wildlife  using AMS.
• February, 2004:  Vitalea Science enters a strategic alliance with Trials by Design , an innovative PK analysis and reporting firm that offers advanced statistical analyses and reporting developed for AMS-based studies.  
• January, 2004: Vitalea Science obtains patents license from Lawrence Livermore National Laboratories  ( LLNL ) to become the  first commercial entity in United States to provide   biological AMS services for both biomedical and pharmaceutical applications.                
• October, 2003:  Vitalea Science moves from development stage to full incorporation status.  Laboratories spaces are identified and populated. 
• September, 2003: Dr. Stephen R. Dueker, President and CEO of  Vitalea Science, Inc. delivers the keynote address "AMS in Phytonutrition" at the International Mass Spectrometry Conference in Edinburgh , Scotland . Click here to view the pdf copy of the address.